The efficacy and safety of arsenic trioxide added transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.

Trial Profile

The efficacy and safety of arsenic trioxide added transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Jan 2014

At a glance

  • Drugs Arsenic trioxide; Epirubicin
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Sep 2012 Status changed from not yet recruiting to completed as reported by Chinese Clinical Trial Register.
    • 15 Sep 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top